Abstract: The present invention generally relates to the field of diagnostic microbiology, and, more particularly, to compositions and methods for detecting and differentiating one or more viruses or other intracellular parasites present in a specimen. The present invention also provides compositions and methods to evaluate the susceptibility of organisms to antimicrobial agents.

Abstract: The present invention relates to a pharmaceutical cocktail and methods of treatment involving said cocktail, in particular, a combination of effective amounts of a carbonic anhydrase inhibitor, in combination with effective amounts of an angiogenesis inhibitor, including a vascular endothelial growth factor (VEGF) inhibitor such as bevacizumab for the treatment of cancer. In other embodiments, it relates to compositions and methods of treating cancer involving effective amounts of a carbonic anhydrase inhibitor. Pharmaceutical compositions and methods of treating cancer (eliminating the tumor, shrinking the tumor, prolonging the life of the patient, increasing quality of life by decreasing the grade of adverse events seen with other cancer treatments, and/or preventing/reducing the likelihood of the tumor's metastases) are additional aspects of the present invention.

Abstract: A relationship between cancer and ribonucleic acid (RNA) regulation is described by determining intracellular levels of niRN A regulators. Generally, mRNA levels are decreased in cancer cells that may be a reflection of either reduced mRNA expression and/or increased mRNA degradation. miRNAs are identified that hybridize to an mRNA that are suspected to mediate intracellular mRNA steady state levels. Alternatively, ribonucleic acid binding protein (RBP) levels may also mediate intracellular mRNA steady state levels. In particular, this invention demonstrates an effective clinical management strategy for uterine cell cancers may be implemented by taking advantage of an exemplary relationship between P2X7 mRNA and miRNAs including, but not limited to, miR-186 and/or miR-150.

Abstract: The invention relates to methods for the treatment of urinary incontinence (UI) and stress urinary incontinence (SUI) in both men and women by replacement of a damaged, absent or injured pubo-urethral ligament (PUL) via a simple injection of “Regenerative Glue.” For example, in the case of UI, the injection of “Regenerative Glue” at the PUL site will adhere the ventral surface of the urethra to the dorsal surface of the symphysis pubis (i.e. the space of Retzius), and further provide regenerative material for continuous replacement of deficient tissues and cells. “The Regenerative Glue” can be made from several commercially available materials including biocompatible glues, fibrin sealant or biocompatible gels; combined with Meschencymal stem cells (MSC) derived from bone marrow or adipose tissues.

Abstract: The invention contemplates a method for sterilizing protein or collagen-based hard and soft tissues, from animal and human donors or created synthetically by exposure to genipin, an active compound found in gardenia fruit extract. Genipin sterilizes the tissues through crosslinking the organic framework of microbes while maintaining or enhancing mechanical strength of the tissue graft by stabilizing the collagen backbone with crosslinks bone allografts experience significant and repetitive loads during their duty cycle, sterilizing bone allografts without causing a loss in biomechanical properties is quite important.